Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

艾伯维宣布，欧盟委员会（EC）已批准RINVOQ®（upadacitinib；15mg，每日一次 ... 类固醇暴露量显著低于接受安慰剂联合52周类固醇减量方案的患者（中位暴露量分别为1615 mg和2882 mg；p<0.001）。 持续完全缓解b：接受RINVOQ 15mg联合26周类固醇减量方案的患者中，37.1% ...

Study patients (age range, ≥12 to <64 years) were randomly assigned 1:1 to receive either upadacitinib 15 mg once daily (n=447) or dupilumab (n=454) per label dosing. All patients had moderate to ...

The efficacy and safety of withdrawing versus continuing upadacitinib in maintaining remission ... CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract ...